• Roche Holdings AG (OTC: RHHBY) announced that the FDA accepted its supplemental marketing application for Polivy.

• Polivy is being developed by Roche using Seagen Inc (NASDAQ: SGEN) ADC technology and is currently being investigated for the treatment of several types of non-Hodgkin lymphoma (NHL).

• Polivy is being used with Rituxan and cyclophosphamide, doxorubicin, and prednisone (R-CHP) for previously untreated diffuse large B-cell lymphoma (DLBCL), an aggressive blood cancer.

• The FDA is expected to decide on approval by April 2, 2023.

• The progression comes on the back of the results from its Phase 3 POLARIX trial.

• The study showed significant improvement in median progression-free survival at a 28.2-month check-in, with the risk of disease progressions reduced by 27% with Polivy plus R-CHP, compared with R-CHOP earning itself a p-value of p=0.02.

• The treatment combo also initially posted a Grade 3-4 side effect rate of 57.7% compared with 57.5% for the SOC chemo combo.

• 3% of patients died in the treatment arm compared with 2.3% in control, and 9.2% in the Polivy arm discontinued due to dosing compared with 13% in the Rituxan-chemo arm.

• Price Action: RHHBY shares are down 1.84% at $41.53 on the last check Tuesday.

See more from Benzinga

• FDA Approves Expanded Use Of Roche's Influenza Treatment

• Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.